Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
01 1Bachem AG
02 1Apicore Pharmaceuticals Private Limited
03 1Azico Biophore India Private Limited
04 1MSN Life Sciences Private Limited
01 1SINCALIDE
02 2Sincalide
03 1sincalide
01 3India
02 1Switzerland
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
NDC Package Code : 55463-0004
Start Marketing Date : 1999-10-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 42973-235
Start Marketing Date : 2017-12-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 69575-4029
Start Marketing Date : 2018-12-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1000g/1000g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 69766-102
Start Marketing Date : 2021-10-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
39
PharmaCompass offers a list of Sincalide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sincalide manufacturer or Sincalide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sincalide manufacturer or Sincalide supplier.
PharmaCompass also assists you with knowing the Sincalide API Price utilized in the formulation of products. Sincalide API Price is not always fixed or binding as the Sincalide Price is obtained through a variety of data sources. The Sincalide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cholecystokinin, CCK Octapeptide (26-33) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cholecystokinin, CCK Octapeptide (26-33), including repackagers and relabelers. The FDA regulates Cholecystokinin, CCK Octapeptide (26-33) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cholecystokinin, CCK Octapeptide (26-33) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cholecystokinin, CCK Octapeptide (26-33) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cholecystokinin, CCK Octapeptide (26-33) supplier is an individual or a company that provides Cholecystokinin, CCK Octapeptide (26-33) active pharmaceutical ingredient (API) or Cholecystokinin, CCK Octapeptide (26-33) finished formulations upon request. The Cholecystokinin, CCK Octapeptide (26-33) suppliers may include Cholecystokinin, CCK Octapeptide (26-33) API manufacturers, exporters, distributors and traders.
click here to find a list of Cholecystokinin, CCK Octapeptide (26-33) suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cholecystokinin, CCK Octapeptide (26-33) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cholecystokinin, CCK Octapeptide (26-33) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cholecystokinin, CCK Octapeptide (26-33) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cholecystokinin, CCK Octapeptide (26-33) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cholecystokinin, CCK Octapeptide (26-33) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cholecystokinin, CCK Octapeptide (26-33) suppliers with NDC on PharmaCompass.
We have 4 companies offering Cholecystokinin, CCK Octapeptide (26-33)
Get in contact with the supplier of your choice:
